An analysis of gemcitabine-resistant cholangiocarcinoma cells

ABSTRACT: Cholangiocarcinoma (CCA) is an aggressive liver bile duct cancer with a poor prognosis. For advanced CCA patients, Gemcitabine (GEM)-based chemotherapy is the standard treatment. Since there is only a 20-30% response rate for advanced CCA patients, it is a critical issue to counteract GEM resistance (GR). We selected two GR iCCA sublines (SSP-25-GR and SNU-1196-GR) from the parental cells (SSP-25 and SNU-1196) to determine the transcriptome profile.

ORGANISM(S): Homo sapiens

PROVIDER: GSE291223 | GEO | 2026/09/16

REPOSITORIES: GEO